NOVOCURE LTD (NVCR) Stock Price, Quote, News and Overview
NASDAQ:NVCR - Nasdaq - JE00BYSS4X48 - Common Stock - Currency: USD
NVCR Quote, Performance and Key Statistics
NOVOCURE LTD
NASDAQ:NVCR (2/7/2025, 8:00:01 PM)
After market: 22.11 -0.14 (-0.63%)22.25
-0.68 (-2.97%)
The current stock price of NVCR is 22.25 USD. In the past month the price decreased by -23.04%. In the past year, price increased by 45.33%.
NVCR Latest News and Analysis
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
Why NovoCure Stock Was Winning Big This Week
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
NVCR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.64 | 223.87B | ||
| ISRG | INTUITIVE SURGICAL INC | 79.53 | 207.65B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.93 | 155.12B | ||
| SYK | STRYKER CORP | 32.11 | 149.21B | ||
| MDT | MEDTRONIC PLC | 17.14 | 115.42B | ||
| BDX | BECTON DICKINSON AND CO | 17.47 | 66.66B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.35 | 41.49B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.77 | 40.04B | ||
| IDXX | IDEXX LABORATORIES INC | 40.87 | 37.65B | ||
| RMD | RESMED INC | 26.8 | 34.78B | ||
| DXCM | DEXCOM INC | 51.81 | 34.40B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 20.51 | 25.64B |
Related stock screener links
About NVCR
Company Profile
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. The company is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. The company also has a license to market Optune in China, Hong Kong, Macau and Taiwan. The company has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Company Info
NOVOCURE LTD
No. 4 The Forum, Grenville Street
Saint Helier JE2 4UF JE
CEO: Asaf Danziger
Employees: 1453
Company Website: https://www.novocure.com/
Investor Relations: https://www.novocure.com/investor-relations/
Phone: 441534756700
NVCR FAQ
What is the stock price of NVCR?
The current stock price of NVCR is 22.25 USD.
What is the symbol for NOVOCURE LTD stock?
The exchange symbol of NOVOCURE LTD is NVCR and it is listed on the Nasdaq exchange.
On which exchange is NVCR stock listed?
NVCR stock is listed on the Nasdaq exchange.
Is NVCR a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for NVCR, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of NVCR.
Does NVCR stock pay dividends?
NVCR does not pay a dividend.
When does NVCR stock report earnings?
NVCR will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of NVCR?
NVCR does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.4).
What is the Short Interest ratio of NVCR stock?
The outstanding short interest for NVCR is 4.98% of its float.
NVCR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to NVCR. When comparing the yearly performance of all stocks, NVCR is one of the better performing stocks in the market, outperforming 90.48% of all stocks.
NVCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCR. Both the profitability and financial health of NVCR have multiple concerns.
NVCR Financial Highlights
Over the last trailing twelve months NVCR reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS decreased by 24.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.26% | ||
| ROE | -41.52% | ||
| Debt/Equity | 1.81 |
NVCR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to NVCR. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 32.92% and a revenue growth 17.94% for NVCR